MLTX Company Profile and Key Details

MoonLake Immunotherapeutics (NASDAQ:MLTX) closed at $17.68 USD, gaining $0.17 (0.97%) from the previous close of $17.51. The stock is currently mid-range between its 52-week high and low $5.95 and $62.75. With a market capitalization of about $1.25 billion, MoonLake Immunotherapeutics is classified as a small-cap and shows market-like volatility (beta ~1.21). Key stats such as the average daily volume over the past year has been around 2.23 million shares, volume is running light vs its 52-week average. Headquartered in Zug, None, MoonLake Immunotherapeutics operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kristian Reich, the company employs approximately 100 people and listed since October 20, 2020. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.

Short-term trend indicators are mixed aligned (SMA20 6.32%, SMA50 14.08%, SMA200 -42.56%). The stock’s 14-day RSI is 58.23 (neutral), while the ATR of 1.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -71.82% below its high and over 197.14% above its low. Average 10-day trading volume of 1.52 million shares is below the 3-month average of 2.16 million, indicating normal recent market interest.

MoonLake Immunotherapeutics last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.01. This means the shares are trading above this model’s fair value.

MoonLake Immunotherapeutics generated EPS of -$3.53 over the past year. Five-year average earnings growth is -256.78%. Wall Street analysts project EPS growth of 11.92% annually over the next five years. The latest quarter delivered EPS of -$1.11. The next quarter is forecast at -$0.89. Next year's EPS is expected at -$42.85. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 12 Buy ratings, 4 Hold ratings, 2 Sell rating and 0 Strong Sell ratings. Price targets range from $85.00 to $5.00. The high target offers 380.77% upside. The low target suggests -71.72% downside. The mean target is $31.09. This offers 75.85% upside. MoonLake Immunotherapeutics earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 05, 2025, missed forecasts by 24.94%. The prior quarter beat by 19.18%. Over the last six quarters, Apple has recorded several small beats. These include 39.74% in August 08, 2024.

MoonLake Immunotherapeutics has 63.50 million shares outstanding. The public float is 24.16 million shares, elevated short interest at 21.68% of float. This equals 6.13 million shares. The short ratio is 12.16 days. Institutional investors hold 112.12% of the float. Insiders own 15.41%. Santos da Silva Jorge holds 2.88 million shares, Chen Bihua has 1.99 million shares and BVF PARTNERS L P/IL has 1.29 million shares. Over the past six months, insider transactions show net selling. They sold 3.21 million shares across 6 transactions.